1. Home
  2. NRP vs ORKA Comparison

NRP vs ORKA Comparison

Compare NRP & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRP
  • ORKA
  • Stock Information
  • Founded
  • NRP 2002
  • ORKA 2004
  • Country
  • NRP United States
  • ORKA United States
  • Employees
  • NRP N/A
  • ORKA N/A
  • Industry
  • NRP Coal Mining
  • ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • NRP Energy
  • ORKA Health Care
  • Exchange
  • NRP Nasdaq
  • ORKA Nasdaq
  • Market Cap
  • NRP 1.4B
  • ORKA 1.2B
  • IPO Year
  • NRP N/A
  • ORKA N/A
  • Fundamental
  • Price
  • NRP $104.99
  • ORKA $27.50
  • Analyst Decision
  • NRP
  • ORKA Strong Buy
  • Analyst Count
  • NRP 0
  • ORKA 7
  • Target Price
  • NRP N/A
  • ORKA $42.86
  • AVG Volume (30 Days)
  • NRP 22.6K
  • ORKA 569.7K
  • Earning Date
  • NRP 11-04-2025
  • ORKA 11-12-2025
  • Dividend Yield
  • NRP 2.89%
  • ORKA N/A
  • EPS Growth
  • NRP N/A
  • ORKA N/A
  • EPS
  • NRP 10.64
  • ORKA N/A
  • Revenue
  • NRP $219,503,000.00
  • ORKA N/A
  • Revenue This Year
  • NRP N/A
  • ORKA N/A
  • Revenue Next Year
  • NRP N/A
  • ORKA N/A
  • P/E Ratio
  • NRP $9.76
  • ORKA N/A
  • Revenue Growth
  • NRP N/A
  • ORKA N/A
  • 52 Week Low
  • NRP $86.83
  • ORKA $5.49
  • 52 Week High
  • NRP $113.04
  • ORKA $31.13
  • Technical
  • Relative Strength Index (RSI)
  • NRP 50.34
  • ORKA 75.30
  • Support Level
  • NRP $102.59
  • ORKA $25.40
  • Resistance Level
  • NRP $108.71
  • ORKA $29.20
  • Average True Range (ATR)
  • NRP 2.73
  • ORKA 2.01
  • MACD
  • NRP -0.38
  • ORKA 0.55
  • Stochastic Oscillator
  • NRP 32.64
  • ORKA 84.56

About NRP Natural Resource Partners LP Limited Partnership

Natural Resources Partners LP is a diversified natural resource company. It is engaged in the business of owning, managing and leasing a diversified portfolio of mineral properties in the United States, including interests in coal, trona and soda ash, crude oil and natural gas, construction aggregates, frac sand, and other natural resources. The company leases coal reserves to experience mine operators under long-term leases that grant the operator the right to mine its coal reserves in exchange for royalty payments. The company operates in two reportable segments namely: Mineral Rights and Soda Ash. the majority of the revenue is generated from the Mineral Rights segment. Geographically, the business activity of the group functions through the United States.

About ORKA Oruka Therapeutics Inc. Common Stock

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Share on Social Networks: